Suchergebnisse - "Zhao, Y"

PubPharm (59)

1

Efficacy and safety of first-line treatment with anti-CD38 monoclonal antibody-based regimen for primary plasma cell leukemia

enthalten in: Zhonghua yi xue za zhi | 2024

von Dou, X. | Liu, R. | Liu, Y. | +14

2

Effect of SLC7A11 gene downregulation on the gefitinib resistance of lung adenocarcinoma PC9/GR cells and its mechanism

enthalten in: Zhonghua zhong liu za zhi [Chinese journal of oncology | 2023

von Jia, Y. | Zhao, Y. | Zhen, S. | +4

3

Effect of imatinib on the height of children with chronic myeloid leukemia in the chronic phase

enthalten in: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi | 2020

von Zheng, F. | Zhang, Y. | Zhang, L. | +25

4

Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly : results from a phase 3, prospective, randomized, and open-label study (LANTERN)

enthalten in: BMC endocrine disorders | 2020

von An, Z. | Lei, T. | Duan, L. | +58

5

Prognostic analysis of definitive radiotherapy for early esophageal carcinoma(T1-2N0M0) : a multi-center retrospective study of Jing-Jin-ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group

enthalten in: Zhonghua zhong liu za zhi [Chinese journal of oncology | 2020

von Lu, N. | Wang, X. | Li, C. | +25

6

Anti-breast cancer activity of resveratrol encapsulated in liposomes

enthalten in: Journal of materials chemistry. B | 2020

von Zhao, Y. | Cao, Y. | Sun, J. | +7

7

Efficacy and safety of vandetanib on advanced medullary thyroid carcinoma : single center result from a phase Ⅲ study

enthalten in: Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery | 2019

von Wang, S. | Zhang, X. | Wang, X. | +8

8

MicroRNA-132 reverses cisplatin resistance and metastasis in ovarian cancer by the targeted regulation on Bmi-1

enthalten in: European review for medical and pharmacological sciences | 2019

von Zhang, X. | Sun, B. | Tian, S. | +3

9

Topoisomerase inhibitor upregulates MICA/B expression in breast cancer cells through ATM/ATR and NF-κB pathway

enthalten in: Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences | 2018

von Zhu, Y. | Shi, Y. | Zhao, Y. | +1

10

Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC) : a pharmacogenomic study of metabolic enzymes and transporters

enthalten in: The pharmacogenomics journal | 2017

von Ma, Y. | Xin, S. | Huang, M. | +11

1
2
3
4
5
6
Nächster »
[6]